Janssen Biotech Inc.

09/10/2020 | Press release | Distributed by Public on 09/10/2020 07:17

Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis